Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 66 of the 67 references it cites were found in a registry or an index.

Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy

Cheymol, Georges · 2000 · Clinical Pharmacokinetics

Abstract

Obesity is a worldwide problem, with major health, social and economic implications. The adaptation of drug dosages to obese patients is a subject of concern, particularly for drugs with a narrow therapeutic index. The main factors that affect the tissue distribution of drugs are body composition, regional blood flow and the affinity of the drug for plasma proteins and/or tissue components. Obese people have larger absolute lean body masses as well as fat masses than non-obese individuals of the same age, gender and height. However, the percentage of fat per kg of total bodyweight (TBW) is markedly increased, whereas that chrome P450 isoforms are altered, but no clear overview of drug hepatic metabolism in obesity is currently available. Pharmacokinetic studies provide differing data on renal function in obese patients. This review analyses recent publications on several classes of drugs: antibacterials, anticancer drugs, psychotropic drugs, anticonvulsants, general anaesthetics, opioid analgesics, neuromuscular blockers, beta-blockers and drugs commonly used in the management of obesity. Pharmacokinetic studies in obesity show that the behaviour of molecules with weak or moderate lipophilicity (e.g. lithium and vecuronium) is generally rather predictable, as these drugs are distributed mainly in lean tissues. The dosage of these drugs should be based on the ideal bodyweight (IBW). However, some of these drugs (e.g. antibacterials and some anticancer drugs) are partly distributed in adipose tissues, and their dosage is based on IBW plus a percentage of the patient's excess bodyweight. There is no systematic relationship between the degree of lipophilicity of markedly lipophilic drugs (e.g. remifentanil and some beta-blockers) and their distribution in obese individuals. The distribution of a drug between fat and lean tissues may influence its pharmacokinetics in obese patients. Thus, the loading dose should be adjusted to the TBW or IBW, according to data from studies carried out in obese individuals. Adjustment of the maintenance dosage depends on the observed modifications in clearance. Our present knowledge of the influence of obesity on drug pharmacokinetics is limited. Drugs with a small therapeutic index should be used prudently and the dosage adjusted with the help of drug plasma concentrations.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-200039030-00004

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 67 references

Research works printed but not linked: 11

  1. 1959, ull, 40, 1
  2. Lehingue, 1996, Rev Epidemiol Sante Publique, 44, 37
  3. Forbes, 1983, Int J Obesity, 7, 99
  4. Leader, 1994, Am J Hosp Pharm, 51, 2155
  5. Bachur, 1979, Cancer Treat Rep, 63, 817
  6. Schwartz, 1991, Anesth Analg, 73, 790
  7. Schwartz, 1992, Anesth Analg, 74, 515
  8. Cheymol, 1995, Br J Clin Pharmacol, 39, 684
  9. Garratt, 1995, J Clin Pharmacol, 35, 928
  10. Caraco, 1995, Int J Obes, 19, 234
  11. Zahorska-Markiewicz, 1996, Int J Clin Pharmacol Ther, 34, 393

Cited by

See all 701

Metadata

Authors
Cheymol, G.
Corresponding author
Cheymol, Georges
Venue
Clinical Pharmacokinetics
Published
2000-09
Volume
39
Issue
3
Pages
215-231
ISSN
0312-5963 (ISSN-L)
OpenAlex
W2107564745
Cited by
631
References
67
Citations by year
2026: 17 · 2025: 30 · 2024: 22 · 2023: 22 · 2022: 24 · 2021: 31 · 2020: 39 · 2019: 25 · 2018: 22 · 2017: 34 · 2016: 32 · 2015: 26 · 2014: 41 · 2013: 27 · 2012: 45
FWCI
0.46
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords
obesity, pharmacokinetics, drug dosing, tissue distribution, body composition, lean body mass, adipose tissue, lipophilicity, ideal body weight, drug clearance, renal function, hepatic metabolism, drug interactions, antibacterial agents, anticancer agents, psychotropic drugs, antiepileptic drugs, general anesthetics, opioid analgesics, neuromuscular blocking agents, beta-blockers, loading dose, therapeutic index
MeSH terms
Adrenergic beta-Antagonists, Anesthetics, Anti-Bacterial Agents, Anticonvulsants, Antifungal Agents, Antineoplastic Agents, Humans, Hypoglycemic Agents, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy. https://app.cochat.ai/papers/10.2165/00003088-200039030-00004
The paper
Cheymol, G. (2000). Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200039030-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.